Kinevac® is developed by Bristol-Myers Squibb.

What development phase is Kinevac® in?

Kinevac® is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Kinevac®

Bristol-Myers Squibb · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Kinevac®
Also known as	Sincalide
Sponsor	Bristol-Myers Squibb
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986278 in Healthy Male Participants (PHASE1)
Impact of Two Genetic Variants of OATP1B3 or MRP2 or Rifampin on Systemic Disposition and Biological Efficacy of CCK-8 (PHASE1)
Ultrasound for Diagnosis of Biliary Dyskinesia (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Kinevac® CI brief — competitive landscape report
Kinevac® updates RSS · CI watch RSS
Bristol-Myers Squibb portfolio CI